NRx Pharmaceuticals secures up to $16M senior secured debt from Anson Funds; settles Streeterville claims

NRX Pharmaceuticals, Inc.

Up to $16.3M principal in three tranches; first tranche $5.435M principal at $5M purchase price.
Notes convertible at lower of $2.4168 or 92% of lowest VWAP; 6% interest, 15-month maturity.
Warrants for 50% of principal/VWAP, 5-year term, exercise at $2.4168 with potential adjustments.
Proceeds to fund 2024 NDA filings for NRX-100 (ketamine) and NRX-101; retire Streeterville debt.
Streeterville settlement: $2.5M at closing plus $3.05M within 60 days; all claims released.

item 1.01 item 2.03 item 3.02 item 5.03 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.